지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.1
- 수록면
- 28 - 40 (13page)
이용수
초록· 키워드
오류제보하기
Objectives: Infliximab and adalimumab are common biologic agents to induce remission state among patients with Crohn’s disease. Although, direct head-to-head studies comparing the clinical outcomes of the two treatments are sparse, several observational trials have been conducted recently. In this study, we performed systematic literature review and meta-analysis of cohort studies to compare the effectiveness of infliximab and adalimumab. Methods: We searched four databases, Ovid-Medline, Embase, PubMED, and Cochran Library. Observational studies comparing infliximab and adalimumab in patients with Crohn’s disease were selected. Quality of studies was assessed, and meta-analysis was conducted using a random effect model. In addition, subgroup analyses were performed based on the diagnostic criteria, biologics naive/relapse and patients’ ethnicity. Results: Of the total 2,209 searched studies, 8 studies were included in the analysis. No significant difference in clinical remission between Infliximab and adalimumab was found [risk ratio (RR) 0.98, 95% confidence interval (CI) 0.90?1.07, heterogeneity: p=0.08, I2=45%]. In subgroup analysis, we found that the effectiveness of adalimumab was significantly better than infliximab (RR 0.77, 95% CI 0.61?0.98) in Asian population, however, due to the insufficient number of included studies for Asian population, careful interpretation is needed. Conclusion: The effectiveness of infliximab and adalimumab is comparable in observational studies. Follow-up studies are needed to find out treatment outcomes in different ethnicity.
목차
등록된 정보가 없습니다.
참고문헌 (16)
참고문헌 신청
김현수 / 2017 / 크론병의 진단과 치료 / 대한의사협회지 60(6):484~490
하정은 / 2019 / 국내 염증성장질환의 약물치료 및 약제비 현황: 2010-2014 국민건강보험자료 활용 연구 / 한국임상약학회지 29(2):79~88
Ananthakrishnan AN / 2016 / Comparative effectiveness of infliximab and adalimumab in Crohn’s disease and ulcerative colitis / Inflamm Bowel Dis 22:880~885
Otake H / 2017 / Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?:a STROBE-compliant retrospective cohort study / Medicine (Baltimore) 96:e6635
Narula N / 2016 / The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn’s disease / Aliment Pharmacol Ther 44:170~180
하정은 / 2019 / 국내 염증성장질환의 약물치료 및 약제비 현황: 2010-2014 국민건강보험자료 활용 연구 / 한국임상약학회지 29(2):79~88
Ananthakrishnan AN / 2016 / Comparative effectiveness of infliximab and adalimumab in Crohn’s disease and ulcerative colitis / Inflamm Bowel Dis 22:880~885
Otake H / 2017 / Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?:a STROBE-compliant retrospective cohort study / Medicine (Baltimore) 96:e6635
Narula N / 2016 / The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn’s disease / Aliment Pharmacol Ther 44:170~180
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Adalimumab or infliximab: which is better for perianal fistula in Crohn’s disease?
Intestinal research
2017 .01
-
Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
Gut and Liver
2021 .01
-
Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
Gut and Liver
2022 .01
-
Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study
Pediatric Gastroenterology, Hepatology & Nutrition
2016 .01
-
Long-term safety and efficacy of adalimumab for intestinal Behçet’s disease in the open label study following a phase 3 clinical trial
Intestinal research
2017 .01
-
Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
Gut and Liver
2016 .01
-
Infliximab, Is It Really a New Horizon for the Treatment of Kawasaki Disease?
Korean Circulation Journal
2019 .01
-
Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis
Gut and Liver
2021 .01
-
Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Spinal Cord Injury
대한신경외과학회지
2015 .01
-
Eruptive Benign Melanocytic Nevi Formation Following Adalimumab Therapy in a Patient with Crohn's Disease
Annals of Dermatology
2016 .01
-
크론병의 진단과 치료
대한의사협회지
2017 .01
-
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Intestinal research
2021 .10
-
Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study
Gut and Liver
2021 .11
-
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Gut and Liver
2021 .01
-
Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn’s disease
Intestinal research
2017 .01
-
Infliximab does not show the ameliorating effects on colitis mice model
한국실험동물학회 학술발표대회 논문집
2019 .07
-
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Intestinal research
2021 .10
-
Pulmonary Sarcoidosis Induced by Adalimumab: A Case Report and Literature Review
Yonsei Medical Journal
2016 .01
-
Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study
Gut and Liver
2015 .01
-
Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn’s Disease: A Nationwide, Multicenter Study
Yonsei Medical Journal
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0